News for Nektar Therapeutics (ITH.BE)

Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company. Last week, Nektar announced that it has entered into a clinical trial collaboration and supply agreement with pharmaceutical giant...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2020 Results Earnings Conference Call February 25, 2021, 5:00 pm ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and...

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 CIK ...

Papa John’s International delivered lower-than-expected earnings in the fourth quarter. Meanwhile, shares of Papa John’s fell 7.4% in pre-market trading as the company posted earnings per share (EPS) of $0.40 during the fourth quarter, which were behind analysts’ expectations of $0.46. That said, revenue increased 12.5% year-on-year to $469.8 million, topping analysts’ estimates of $465.7 million. The increase in 4Q revenues was primarily attributable to higher comparable sales for North America restaurants, which saw 10.2% growth in company owned restaurants and 14.5% growth in franchised restaurants. Papa John’s (PZZA) international sales also increased on the back of higher commissary revenues and royalties resulting from comparable sales growth of 21.4%. For fiscal 2020, the company generated sales of $1.81 billion, up 12% from 2019. Diluted earnings per share came in at $1.40, versus $0.03 in the comparable year-ago period. Papa John’s President and CEO Rob Lynch said, “4Q was the third consecutive quarter of double-digit comparable sales growth and the sixth straight quarter of positive comparable sales in North America. We ended the year with the launch of Epic Stuffed Crust, the biggest product innovation in the company’s history, and our future is extremely bright.” In light of ongoing uncertainity about the future impact from the COVID-19 pandemic, Papa John’s did not provide any guidance. (See Papa John’s stock analysis on TipRanks) On Feb. 23, Deutsche Bank analyst Brian Mullan raised the price target to $110 (7.2% upside potential) from $91 and reiterated a Buy rating. Mullan believes the outlook for Papa John’s shares from here is favorable with a 12-month view. Turning to Wall Street, Papa John’s has a Strong Buy consensus rating based on 8 Buys and 1 Hold. The average analyst price target of $111.13 implies about 8.3% upside potential from current levels. Papa John’s stock has seen a runup of about 50% over the past year. Related News: Fisker Inks MOU With Foxconn To Develop EV; Shares Pop 22% Pre-Market Upwork Posts Better-Than-Expected 4Q Results; Shares Pop 18.7% After-Hours Nvidia Posts Better-Than-Expected 4Q Earnings; Street Remains Bullish More recent articles from Smarter Analyst: Jumia 4Q Revenues Miss Estimates, Losses Narrow To €40M Radian Group’s 4Q Earnings Beat Estimates; Street Sees 29% Upside Moderna Plans To Increase Supply Capacity For COVID-19 Vaccine; Shares Spike 5% Bilibili’s 4Q Sales Beat Analysts’ Estimates; Shares Rise 3.8%

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings at $0.23 per share on revenue of $4.78 ...

DTE Energy posted better-than-expected earnings in the fourth quarter, as the diversified energy company saw an increase in customer demand for natural gas. The Detroit-based company’s 4Q earnings rose 3% to $1.39 per share on a year-over-year basis and beat Street estimates of $1.24 per share. DTE Energy’s (DTE) earnings from its natural gas utility segment came in at $84 million, up 31% year-over-year. The electric utility earnings amounted to $102 million, down 20.3%. For 2021, the company reaffirmed its outlook and expects adjusted EPS to come in at a range of $6.88 to $7.26, versus the consensus of $7.16. (See DTE stock analysis on TipRanks) DTE CFO David Ruud said, “We are well positioned for another solid year in 2021 as we continue to invest in reliability and infrastructure improvements for our customers.” DTE Energy also announced the progress on the spin-off of its non-utility natural gas pipeline, storage, and gathering business into a new and independent publicly-traded company. The company has initiated the Form 10 registration process with the Securities and Exchange Commission (SEC). The planned move will enhance focus on key customers and is likely to provide faster growth, the company said. The spin-off, which was announced in Oct. 2020, is expected to be completed by mid-year 2021. The transaction awaits the board of directors’ final approval and other regulatory approvals. On Jan. 21, Evercore ISI analyst Durgesh Chopra upgraded the stock’s rating to Buy from Hold and increased the price target to $134 (11.5% upside potential) from $121, as “the firm shook up its Energy sector ratings with a cautious view on the group in the near-term and a preference for value over quality.” The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 2 analysts suggesting a Buy and 3 analysts recommending a Hold. The average analyst price target of $133 implies around 11% upside potential to current levels. Shares have appreciated 5% over the past six months. DTE Energy scores a 9 of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: CAE’s Quarterly Profit Lags Estimates Amid Air Travel Slump Moody’s Posts Better-Than-Expected 4Q Revenue But Profit Disappoints Lincoln Electric Posts Better-Than-Expected Quarterly Profit; Street Sees 5% Upside More recent articles from Smarter Analyst: Motosport Snaps Up KartKraft; Street Sees 41% Upside Dynavax’s Hepatitis B Vaccine Authorized In Europe; Shares Rise 6% Coca-Cola Seeks Controlling Stake In BodyArmor Sports Drink - Report Appian Posts Smaller-Than-Feared 4Q Loss; Shares Drop 6%

Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking u...

Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in ...

SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ --?Nektar Therapeutics? will announce its financial results for the fourth quarter and year-ended December 31, 2020, on?Thursday, February... | February 18, 2021

Today's Daily Dose brings you news about Nektar's collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma's strategic financing; and vTv Therapeutics' initiation of a phase 1 multiple ascending dose study of HPP737.

As the Dow, S&P 500, and Nasdaq keep up the good news, Q.ai's Artificial Intelligence systems have crunched the data to give you today's best short plays.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.39%

Presidente eletto Biden potrebbe risultare sotto pressione per portare avanti la riforma dei prezzi dei farmaci. Ma in un anno in cui l'attenzione principale sar rivolta alle strategie per... | January 22, 2021

Thomas Egger, [email protected] www.bbbiotech.com Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in... | January 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 5) Curis, ...